Synapticure is a virtual-first neurological care company founded in 2017. It provides patients with neurodegenerative diseases such as ALS with fast access to expert neurologists, coordinated and personalised care across every stage of illness, entry to clinical trials and emerging treatments, and wraparound support. The company is licensed to practise in all 50 US states.
The care model combines telehealth delivery with an interdisciplinary clinical workforce. Its technical domains span virtual-first telehealth care delivery, neurology and neurodegenerative disease care, clinical trials matching and access, genetic counselling, mental health services and care coordination. Products include the virtual-first neurological care model, an access programme for clinical trials and treatments, and a suite of wraparound support services covering care coordination, genetic counselling and mental health care for patients and caregivers.
The company was born of a personal event: co-founder Brian Wallach was diagnosed with ALS in 2017 at the age of 37. That origin shapes a patient- and caregiver-first philosophy and an emphasis on proactive, compassionate care. The team brings together neurologists, subspecialists, genetic counsellors, mental health providers and care coordinators, with a stated commitment to personalised, comprehensive care at all stages of neurodegenerative disease.
Synapticure operates across the United States, with its practice licensed in all 50 states. Its industry verticals include healthcare, neurology, telehealth and virtual care, neurodegenerative disease, clinical trials and care management.
